title: [Protective effects of d-chlorpheniramine maleate pre-treatment against acute side effects of Irinotecan(CPT- 11)].
abstract: It is wellknown that cholinomimetic side effects, such as sedation, abdominal pain, nasal flow and watery eyes, may develop in patients in the early stage of Irinotecan (CPT-11) administration; however, there have been no investigations concerning methods for preventing the development of these side effects. To assess the protective effects of pre-treatment with d-CM on cholinomimetic side effects in the early stage after Irinotecan (CPT-11) administration, we prescribed d- Chlorpheniramine maleate (d-CM) to a group of patients prior to Irinotecan (CPT-11) administration. Twenty members from the group of non-d-CM-treated patients (n=39) and 4 members from the group of treated patients (n=20) complained of side effects. The pre-administration of d-CM significantly reduced the number of patients with side effects (p<0.05). The relative risk (RR) for the frequency of side effects was 0.39 (95% CI; 0.15-0.98), demonstrating that the frequency of side effects was significantly reduced. Based on theses findings, we concluded that the pre-administration of d-CM had protective effects against side effects that might develop in the early stage after Irinotecan (CPT-11) administration.
authors.affiliation: Dept. of Pharmacy, National Hospital Organization Kumamoto Medical Center, Japan.
authors.forename: Nobuhiro
authors.initials: N
authors.lastname: Misumi
authors.forename: Mikako
authors.initials: M
authors.lastname: Hiraike
authors.forename: Fusako
authors.initials: F
authors.lastname: Nawata
authors.forename: Mirai
authors.initials: M
authors.lastname: Hashimoto
authors.forename: Kayoko
authors.initials: K
authors.lastname: Tanigawa
authors.forename: Izumi
authors.initials: I
authors.lastname: Takase
authors.forename: Aya
authors.initials: A
authors.lastname: Nabeshima
authors.forename: Shinobu
authors.initials: S
authors.lastname: Honda
mesh_terms: D000208:Acute Disease; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use; D002166:Camptothecin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002744:Chlorpheniramine / Q000494:pharmacology*; D005260:Female; D006801:Humans; D000077146:Irinotecan; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D002744:Chlorpheniramine; D000077146:Irinotecan; D002166:Camptothecin